351 results on '"Manos, Michael"'
Search Results
2. Germline variants associated with toxicity to immune checkpoint blockade
3. Examining the Role of Language in Play among Children with and without Developmental Disabilities
4. Specific oncogene activation of the cell of origin in mucosal melanoma
5. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors
6. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
7. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
8. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
9. Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
10. Supplementary Figure 3 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
11. Supplementary Figure 2 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
12. Supplementary Figure 5 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
13. Supplementary Figure legends from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
14. Supplementary Figure 4 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
15. 218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient pan-cancer cohort
16. Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
17. Supplementary Figure 1 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
18. 578 Anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans
19. In Reply: A new paradigm for adult ADHD
20. Elementary and Middle School Teachers' Self-Reported Use of Positive Behavioral Supports for Children with ADHD: A National Survey
21. Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade
22. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
23. EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade
24. Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients
25. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
26. Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
27. Abstract 3249: Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors
28. Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
29. Abstract 965: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma
30. Abstract 5864: An angiogenic target of immune exclusion with checkpoint blockade in melanoma
31. Data from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
32. Supplementary Table 5 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
33. Supplemental Figure and Table Legends from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
34. Supplementary Table 2 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
35. Data from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
36. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
37. Supplementary Table 7 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
38. Supplementary Tables 1 through 4 from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
39. Supplementary Figures 1 through 6 from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
40. Data from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
41. Table S1 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
42. Supplementary Table 1 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
43. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
44. Supplementary Table 3 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
45. Supplementary Table 4 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
46. Supplementary Table 6 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
47. Supplementary Methods from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
48. Supplementary Figures and Legends from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
49. Supplemental Figures and Tables from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
50. Development of an Objective Autism Risk Index Using Remote Eye Tracking
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.